Search research articles
Contact Us
Filters
Showing results (71-80 of 179) with videos related to
Page
of 18
Sort By:
Sarcoma
|
December 11, 2012
Bone sarcomas: from biology to targeted therapies
Nathalie Gaspar, Angela Di Giannatale, Birgit Geoerger, et al.
Nature Cancer
|
April 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Arash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium
Uri Ilan, Alba Rubio-San-Simón, Natasha van Eijkelenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2024
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors
Nicolas André, Marie Cécile Le Deley, Clémence Léguillette, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2017
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 24, 2018
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Patrick Schöffski, Agnieszka Wozniak, Michael G Leahy, et al.
JCO Precision Oncology
|
January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Pediatric Blood & Cancer
|
August 25, 2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno, Herve Rubie, Amalia Varo, et al.
The Lancet. Oncology
|
November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
Birgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 22, 2021
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
Birgit Geoerger, Bruce Morland, Irene Jiménez, et al.
Page
of 18
Search research articles
Search
Showing results (71-80 of 179) with videos related to
Sort By:
Page
of 18
Sarcoma
|
December 11, 2012
Bone sarcomas: from biology to targeted therapies
Nathalie Gaspar, Angela Di Giannatale, Birgit Geoerger, et al.
Nature Cancer
|
April 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Arash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium
Uri Ilan, Alba Rubio-San-Simón, Natasha van Eijkelenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2024
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors
Nicolas André, Marie Cécile Le Deley, Clémence Léguillette, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2017
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 24, 2018
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'
Patrick Schöffski, Agnieszka Wozniak, Michael G Leahy, et al.
JCO Precision Oncology
|
January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Pediatric Blood & Cancer
|
August 25, 2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno, Herve Rubie, Amalia Varo, et al.
The Lancet. Oncology
|
November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
Birgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 22, 2021
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
Birgit Geoerger, Bruce Morland, Irene Jiménez, et al.
Page
of 18